Melissa Mendez, MD
Urology · Silver Spring, MDNPI 1467719385
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Coloplast accounts for 71.3% of it on its own, with 47 other manufacturers making up the rest. 2025 is the largest year on record at $23,401, 4.3 times the $5,402 reported in 2019. Among urology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 488 payments — averaging $124.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$43K
- Boston Scientific$6K
- Endo Pharmaceuticals Inc.$4K
- Astellas Pharma US Inc$1K
- Axonics, Inc.$785
- Johnson & Johnson$583
- plus $4K from 42 others
What the payments were for
- Consulting fees$21,03535%
- Travel & lodging$16,90628%
- Food & beverage$22,41637%
- Education$3141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,670 in reported general payments places this provider in the 90th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 119 | $123,116 |
| GemtesaVibegron | 58 | $56,826 |
| Trospium Chloride ErTrospium Chloride | 35 | $6,795 |
| Trospium Chloride | 67 | $5,428 |
| Methenamine Hippurate | 50 | $4,976 |
| Estradiol | 44 | $2,753 |
| Tamsulosin Hcl | 120 | $2,144 |
| Solifenacin Succinate | 18 | $1,824 |
| Finasteride | 88 | $1,642 |
| Testosterone Cypionate | 27 | $1,477 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,419 |
| NitrofurantoinNitrofurantoin Macrocrystal | 23 | $558 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 14 | $458 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 14 | $416 |
| Cefdinir | 31 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,222 | $123,116119 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $285 | $56,82658 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Maryland.
Other urology in Silver Spring
- Anup VoraSilver Spring$58K
- Philip KoiSilver Spring$14K
- Matthew AllawayCumberland$20.6M
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Laura GiustoOwings Mills$367K
- Amin HeratiBaltimore$160K
- Rian DicksteinHanover$144K
- Max KatesBaltimore$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.